Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Ophthalmic Surgery, Lasers & Imaging Retina|February 20, 2013
Comparative effectiveness of the dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to central retinal vein occlusionAdeel H Shaikh, Michael R Petersen, Robert A Sisk, et al.
Clinical Ophthalmology (Auckland, N.Z.)|January 6, 2017
Comparison of outcomes: scleral buckling and pars plana vitrectomy versus vitrectomy alone for primary repair of rhegmatogenous retinal detachmentLuke B Lindsell, Robert A Sisk, Daniel M Miller, et al.
Ophthalmic Surgery, Lasers & Imaging : the Official Journal of the International Society for Imaging in the Eye|September 10, 2011
Outcomes of 25-gauge pars plana vitrectomy in the surgical management of proliferative diabetic retinopathyScott D Schoenberger, Daniel M Miller, Christopher D Riemann, et al.
Retina (Philadelphia, Pa.)|June 22, 2012
Fundus autofluorescence findings of choroidal osteomaRobert A Sisk, Christopher D Riemann, Michael R Petersen, et al.
Ophthalmology|December 8, 2004
Long-term follow-up of indocyanine green-assisted peeling of the retinal internal limiting membrane during vitrectomy surgery for idiopathic macular hole repairAndrea P Da Mata, Scott E Burk, Robert E Foster, et al.
Eye (London, England)|September 3, 2020
Analysis of optical coherence angiography in cystoid macular oedema associated with gyrate atrophyAhmad M Mansour, Ayman G Elnahry, Koushik Tripathy, et al.
Ophthalmic Surgery, Lasers & Imaging Retina|January 7, 2015
Cost comparison of intravitreal aflibercept with bevacizumab and ranibizumab for the treatment of wet age-related macular degenerationAdeel H Shaikh, Brian W Toussaint, Daniel M Miller, et al.
Ophthalmology|December 3, 2011
Analysis of outcomes for intravitreal bevacizumab in the treatment of choroidal neovascularization secondary to ocular histoplasmosisDouglas A Cionni, Shawn A Lewis, Michael R Petersen, et al.
Retina (Philadelphia, Pa.)|July 25, 2022
INTRAVITREAL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR FOR THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO OCULAR HISTOPLASMOSIS: Ten-Year Follow-UpNicholas E Dudenhoefer, Carl W Noble, Michael R Petersen, et al.
Clinical Ophthalmology (Auckland, N.Z.)|March 24, 2021
Outcome of Off-Label AREDS 2 Supplementation for the Treatment of Macular Degeneration in Non-Proliferative Idiopathic Type 2 Macular TelangiectasiaTyler A Berger, Matthew W Manry, Lucas B Lindsell, et al.
Pageof 3